在缺血性中风的二次预防中优先考虑抗高血压剂:一项基于人口的回顾性研究
Hsin-Yu Chen1,2,3, Wei-Kai Lee4,5, Yao-Min Hung6,7,8
1Division of Nephrology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
CNS drugs
|September 23, 2025
概括
血管激素转化酶抑制剂/血管激素II受体阻断剂 (ACEI/ARB) 和通道阻断剂 (CCB) 显著降低了复发性缺血性中风的风险. 与ACEI相比,ARB使用进一步减少了与中风相关的死亡.
科学领域:
- 心血管医学 心血管医学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性缺血性中风 (IS) 带来了显著的死亡率和发病率.
- 对于二次IS预防的最佳一线抗高血压疗法仍在争论中.
- 现实世界的数据对于指导临床决策至关重要.
研究的目的:
- 评估不同抗高血压药物在预防复发性缺血性中风方面的实际有效性.
- 为了比较血管激素转化酶抑制剂/血管激素II受体阻断剂 (ACEI/ARB) 和通道阻断剂 (CCB) 与其他抗高血压药物 (OHTND).
主要方法:
- 使用台湾国家医疗保险研究数据库 (2000-2020) 进行的回顾性队列研究.
- 倾向性得分权重,以平衡治疗组之间的共变量 (OHTND,ACEI/ARB,CCB).
- 考克斯的比例危险模型分析了复发性IS,死亡率和主要不良心脏和脑血管事件 (MACCE) 的风险.
主要成果:
- 与OHTND相比,ACEI/ARB和CCB队列的复发性IS风险显著降低 (分别为14%和15%)
- 使用CCB与急性心肌梗塞的风险 (37%) 与OHTND相比较高.
- 与ACEI使用者相比,ARB使用者的IB复发风险降低了22%,中风相关死亡风险降低了46%.
结论:
- ACEI/ARB使用后急性IS与降低复发性缺血性中风风险有关.
- 结果与现有的随机对照试验 (RCT) 相一致,并填补了第一线药剂选择方面的知识空白.
- 与ACEI相比,ARB在二次IS预防方面显示出更好的结果.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
556
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
556
Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Hypertension III: Clinical Manifestations and Diagnostic Studies
433
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
433
Atherosclerosis IV: Nursing Management
337
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
337
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290


